Auto saved by Logseq

pages/STOP2030___Web___Posts.md

@@ -23,31 +23,7 @@
 	  
 	  The general goals of the REALISE study are to validate the benefits of the FDC through this pragmatic trial within the context of a mass drug administration (MDA) program, to evaluate safety as a primary endpoint, and effectiveness profile as a secondary endpoint, in a large population of school-aged children.
 	  
-	  The clinical trial will have two arms, randomized by school. One arm will receive a single dose of the fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and
+	  The clinical trial will have two arms, randomized by school. One arm will receive a single dose of the fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and 14 years old; alb 400mg/ivm 18mg for those aged 15-17), while the other arm, serving as an active control group, will receive a single dose of albendazole 400mg, the current standard.
-	  14 years old; alb 400mg/ivm 18mg for those aged 15-17), while the other arm,
-	  serving as an active control group, will receive a single dose of albendazole
-	  400mg, the current standard.
 	  
-	  
+	  If you want to review the full protocol, please visit the REALISE study's page on clinicaltrials.gov or PACTR (trial id: PACTR202402529220760).
-	  
+	  #+END_VERSE
-	  If you want to review the full
-	  protocol, please visit the REALISE study's page on [clinicaltrials.gov](https://urldefense.com/v3/__http:/clinicaltrials.gov/__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncV4ibvmQ$) or PACTR (trial id:
-	  PACTR202402529220760).
-	  #+END_VERSE At STOP2030, we aim to provide a pharmacological tool that aids in achieving the WHO's goals for soil-transmitted helminthiasis (STH) by 2030. That's why we are thrilled to announce that the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our most ambitious clinical trial yet, has been registered on clinicaltrials.gov and the Pan African Clinical Trial Registry (id number PACTR202402529220760).
-	  
-	  This randomized control trial is a Cohort Event Monitoring study designed to evaluate the safety and effectiveness of our fixed-dose coformulation (FDC) of albendazole and ivermectin in large
-	  populations, compared to the standard dose of albendazole currently used against STH. We plan to recruit around 20,000 school-aged children between 5 and 17 years old in Kenya and Ghana, starting the the second semester of 2024.
-	  
-	  The general goals of the REALISE study are to validate the benefits of the FDC through this pragmatic trial within the context of a mass drug administration (MDA) program, to evaluate safety as a primary endpoint, and effectiveness profile as a secondary endpoint, in a large population of school-aged children.
-	  The clinical trial will have two
-	  arms, randomized by school. One arm will receive a single dose of the
-	  fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and
-	  14 years old; alb 400mg/ivm 18mg for those aged 15-17), while the other arm,
-	  serving as an active control group, will receive a single dose of albendazole
-	  400mg, the current standard.
-	  
-	  
-	  
-	  If you want to review the full
-	  protocol, please visit the REALISE study's page on [clinicaltrials.gov](https://urldefense.com/v3/__http:/clinicaltrials.gov/__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncV4ibvmQ$) or PACTR (trial id:
-	  PACTR202402529220760).